Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PISCES I: Precision Implemented Smoking Cessation Evaluation Study
NCT04604509Phase 4Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2020
- Primary completion
- Dec 2028
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of varenicline and bupropion in Tobacco Use Disorder (TUD) (7 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: End of treatment seven-day point prevalence at 6 months, Expired carbon monoxide value at 6 months and 1 more. Started Aug 2020; status: recruiting.
02
Drugs
vareniclinebupropion
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT04604509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604509.